# Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

> **NCT00006903** · PHASE2 · UNKNOWN · sponsor: **Gynecologic Oncology Group** · enrollment: 67 (actual)

## Conditions studied

- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IV Uterine Corpus Cancer AJCC v7

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00006903
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-08-30
- **Primary completion:** 2008-03-17
- **Final completion:** —
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006903, "Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*